United States Hip Reconstruction Market Outlook to 2025
June 2018
104
About the Report
About the Report
United States Hip Reconstruction Market Outlook to 2025
Summary
GlobalData's new report, United States Hip Reconstruction Market Outlook to 2025, provides key market data on the United States Hip Reconstruction market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market categories-Hip Resurfacing, Partial Hip Replacement, Primary Hip Replacement and Revision Hip Replacement.
The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.
Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.
Scope
- Market size and company share data for Hip Reconstruction market categories-Hip Resurfacing, Partial Hip Replacement, Primary Hip Replacement and Revision Hip Replacement.
- Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided from 2015 to 2025.
- 2017 company share and distribution share data for Hip Reconstruction market.
- Global corporate-level profiles of key companies operating within the United States Hip Reconstruction market.
- Key players covered include Stryker Corp, Zimmer Biomet Holdings Inc, DePuy Synthes Inc and Others.
Reasons to buy
- Develop business strategies by identifying the key market categories poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market categories expected to register strong growth in the near future.
- What are the key distribution channels and what's the most preferred mode of product distribution-Identify, understand and capitalize.
Products
Products
Orthopedic Devices, Arthroscopy Devices, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Orthobiologics, Orthopedic Bone Cement and Casting Materials, Orthopedic Power Tools, Orthopedic Prosthetics, Orthotic Devices, Other Joint Reconstruction, Spinal Surgery, Trauma Fixation, Value (USD), Volume (units), Revenues, Average Price, Company Share, Distribution Share by Revenue, Company Share by Revenue, Pipeline Products, News, Deals, Key Companies, DePuy Synthes Inc, Zimmer Biomet Holdings Inc, Stryker Corp, Otto GmbH & Co KG, Medtronic plc, Smith & Nephew Plc, Ossur hf, Arthrex Inc, DJO Global Inc, e-life International Co., Ltd. Essity Aktiebolag
Companies
Zimmer Biomet Holdings Inc
DePuy Synthes Inc
Stryker Corp
Exactech Inc
Smith & Nephew Plc
MicroPort Orthopedics Inc
Table of Contents
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 What Is This Report About? 7
2.2 Hip Reconstruction Market Segmentation 7
2.3 Definitions of Markets Covered in the Report 8
3 Hip Reconstruction Market, United States 10
3.1 Hip Reconstruction Market, United States, Revenue (USDm), 2015-2025 10
3.1.1 Partial Hip Replacement Market, United States, Revenue (USDm), by Segment, 2015-2025 13
3.1.2 Primary Hip Replacement Market, United States, Revenue (USDm), by Segment, 2015-2025 15
3.2 Hip Reconstruction Market, United States, Volume (Units), 2015-2025 17
3.2.1 Partial Hip Replacement Market, United States, Volume (Units), by Segment, 2015-2025 19
3.2.2 Primary Hip Replacement Market, United States, Volume (Units), by Segment, 2015-2025 21
3.3 Hip Reconstruction Market, United States, Average Price (USD), 2015-2025 23
3.4 Hip Reconstruction Market, United States, Distribution Share by Revenue (USDm), 2017 25
3.5 Hip Reconstruction Market, United States, Company Share by Revenue (USDm), 2017 26
4 Overview of Key Companies in United States, Hip Reconstruction Market 28
4.1 Zimmer Biomet Holdings Inc 28
4.1.1 Company Overview 28
4.2 DePuy Synthes Inc 28
4.2.1 Company Overview 28
4.3 Stryker Corp 28
4.3.1 Company Overview 28
4.4 Exactech Inc 28
4.4.1 Company Overview 28
4.5 Smith & Nephew Plc 29
4.5.1 Company Overview 29
4.6 MicroPort Orthopedics Inc 29
4.6.1 Company Overview 29
5 Hip Reconstruction Market Pipeline Products 30
6 Financial Deals Landscape 31
6.1 Debt Offerings 31
6.1.1 Zimmer Biomet Raises USD450 Million in Public Offering of Notes Due 2021 31
6.2 Equity Offerings 33
6.2.1 Amedica Files Registration Statement for Rights Offering of Units for up to USD11.4 Million 33
6.3 Private Equity 35
6.3.1 TPG Capital Amends Agreement to Acquire Exactech 35
6.3.2 JANA Partners Denies Rumor to Acquire Certain Stake in Zimmer Biomet 37
6.4 Venture Financing 38
6.4.1 Active Implants Raises USD3.3 Million in Venture Financing 38
6.4.2 OrthAlign Raises USD7.6 Million in Financing 39
7 Recent Developments 40
7.1 Corporate Communications 40
7.1.1 May 14, 2018: OMNIlife science Appoints Rick Epstein as Chief Executive Officer 40
7.1.2 Apr 30, 2018: HSS Surgeon Michael L. Parks, MD, Named President of Orthopaedic Research and Education Foundation 40
7.1.3 Apr 05, 2018: ADAPT Pharma Welcomes Surgeon General Naloxone Advisory 41
7.1.4 Mar 19, 2018: Zimmer Biomet Appoints Coleman N. Lannum as Senior Vice President of Investor Relations 42
7.1.5 Mar 13, 2018: Orthofix Announces Appointment of John Sicard to Board of Directors 42
7.1.6 Mar 05, 2018: Henry Ford Health System Appoints Adnan Munkarah As New Executive Vice President & Chief Clinical Officer 42
7.1.7 Mar 05, 2018: Orthopaedic Industry Veteran Jeffrey R. Binder Joins Bill Petty, MD, as Co-Executive Chairman of Exactech; Daniel Hann Joins Exactech as Sr. Vice President of Business Development 43
7.1.8 Feb 20, 2018: Onconova Announces Presentation on its Acute Myeloid Leukemia Drug Candidate ON-150030 at 2018 American Chemical Society National Meeting and Expo 43
7.1.9 Dec 19, 2017: Zimmer Biomet Announces Appointment of Bryan C. Hanson as President and Chief Executive Officer 44
7.1.10 Dec 12, 2017: Stryker announces Mr. Howard E. Cox, Jr. will retire from Board of Directors 45
7.1.11 Dec 08, 2017: Henry Ford Cardiologist Named to American College of Cardiology Executive Leadership 45
7.1.12 Sep 26, 2017: Pharming Group and HAEi International Patient Organization announce partnership with Inceptua Medicines Access for HAEi Global Access Program” 46
7.1.13 Sep 06, 2017: GE Healthcare: Untangling the wires using MRI research to help understand the brain 47
7.1.14 Aug 23, 2017: Henry Ford Hospital CEO Announces Retirement 48
7.1.15 Aug 02, 2017: Stryker announces election of new Director, Mary K. Brainerd 49
7.1.16 Jul 19, 2017: Mr. Stephen Ooi, Former Zimmer Executive, Newly Appointed as Independent Board Director of XinRong Medical 49
7.1.17 Jul 11, 2017: Zimmer Biomet Announces Leadership Transition 50
7.1.18 Jun 26, 2017: Henry Ford Welcomes Three New Senior Executives 50
7.2 Financial Announcements 51
7.2.1 Apr 30, 2018: Orthofix Announces First Quarter 2018 Financial Results 51
7.2.2 Apr 26, 2018: Zimmer Biomet Reports First Quarter 2018 Financial Results 52
7.2.3 Apr 26, 2018: Stryker reports first quarter 2018 operating results 52
7.2.4 Feb 26, 2018: Orthofix International Reports Fourth Quarter And Fiscal 2017 Financial Results 53
7.2.5 Feb 22, 2018: Can Fite Announces the Submission of Safety Reports for Namodenoson to FDA and other Regulatory Authorities 54
7.2.6 Jan 30, 2018: Zimmer Biomet Announces Fourth Quarter and Full-Year 2017 Results 56
7.2.7 Jan 30, 2018: Stryker reports 2017 results and 2018 outlook 57
7.2.8 Jan 09, 2018: Stryker provides 2017 preliminary net sales results 58
7.2.9 Jan 09, 2018: Orthofix Announces Preliminary 2017 Fourth Quarter and Full Year Net Sales Results 58
7.2.10 Nov 01, 2017: Zimmer Biomet Reports Third Quarter 2017 Financial Results 59
7.2.11 Oct 30, 2017: Orthofix International Reports Third Quarter 2017 Financial Results 60
7.2.12 Oct 30, 2017: Exactech Q3 Revenue USD61.4 Million 61
7.2.13 Oct 26, 2017: Stryker reports third quarter 2017 results 61
7.2.14 Oct 06, 2017: Bruker Introduces Fungiplex Candida Assay into European Clinical Microbiology Markets 62
7.2.15 Oct 06, 2017: Integra LifeSciences launches Revize Collagen Matrix for Plastic and Reconstructive Surgery 65
7.2.16 Sep 26, 2017: Psychemedics Announces Addition of FDA-Cleared Benzodiazepines Hair Test 65
7.2.17 Sep 26, 2017: Moleculin Announces FDA Approval of Annamycin IND 67
7.2.18 Sep 22, 2017: Amedica Releases First and Second Quarter 2017 Preliminary Unaudited Earnings Report and Business Update 68
7.2.19 Sep 07, 2017: MannKind Responds to Hurricane Harvey Devastation with Afrezza Donation 69
7.2.20 Aug 07, 2017: Orthofix International Reports Second Quarter 2017 Financial Results 71
7.2.21 Jul 27, 2017: Zimmer Biomet Reports Second Quarter 2017 Financial Results 71
7.2.22 Jul 27, 2017: Stryker reports second quarter 2017 results 72
7.2.23 Jul 27, 2017: Exactech Q2 Revenue USD67.3 Million On Continuing Strong Extremities Revenue 73
7.2.24 Jul 11, 2017: Zimmer Biomet Reports Certain Preliminary Second Quarter 2017 Results 74
7.2.25 Jun 20, 2017: IsoRay Announces Study Published in The International Journal of Radiation Oncology, Biology, Physics entitled, Clinical Outcomes of Large Brain Metastases Treated with Neurosurgical Resection and Intraoperative Cesium-131 Brachytherapy: Results of 74
7.2.26 Jun 08, 2017: Amedica Releases 2016 Preliminary Earnings Report and Business Update 76
7.2.27 Jun 03, 2017: Longer Term Follow-Up Data with Mercks KEYTRUDA (pembrolizumab) in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) to Be Presented at 2017 ASCO Annual Meeting 77
7.3 Government and Public Interest 79
7.3.1 Mar 09, 2018: HSS Study Finds Consensus Needed for Joint Replacement Performance Measurement 79
7.3.2 Aug 29, 2017: ivWatch Awarded New Innovative Technology Contract From Vizient 80
7.4 Legal And Regulatory 81
7.4.1 May 16, 2018: Zimmer Biomet Statement on Warsaw North Campus FDA Inspection 81
7.4.2 Apr 12, 2018: Sonova Showcases Expanded Product Portfolio at AAA 2018 81
7.4.3 Feb 22, 2018: GTx Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence Accepted for Podium Presentation at SUFU 83
7.4.4 Dec 01, 2017: Amedica Receives Positive Nasdaq Listing Decision 83
7.4.5 Aug 30, 2017: Medovex Corporation to Present at the 19th Annual Rodman & Renshaw Global Investment Conference 84
7.4.6 Aug 09, 2017: Novadaq Receives Court Approval for Arrangement With Stryker 84
7.4.7 Jun 14, 2017: Glenmark Pharmaceuticals receives tentative ANDA approval for Saxagliptin Tablets, 2.5 mg and 5 mg 84
7.4.8 Jun 13, 2017: Zimmer Biomet Holdings Announces Resolution of FDA Warning Letter Related to Its Zhejiang, China Manufacturing Facility 85
7.4.9 May 30, 2017: CSA Medical Announces Expansion of truFreeze Label to Include Barrett's Esophagus with High Grade Dysplasia 85
7.5 Other Significant Developments 86
7.5.1 Mar 08, 2018: Geisinger Announces It Will Stand Behind Cost of Hip Surgery for a Lifetime 86
7.5.2 Dec 06, 2017: Advanced, Minimally Invasive Hip and Knee Replacement Procedures Offered at Wilcox Medical Center 87
7.5.3 Nov 21, 2017: Littleton Adventist to offer robotic technology for knee replacements 87
7.5.4 Nov 02, 2017: ZS-9 (sodium zirconium cyclosilicate) Phase III long-term safety and efficacy data presented at ASN Kidney Week 2017 88
7.5.5 Oct 04, 2017: Zimmer Biomet Provides Update on Manufacturing Facilities in Guaynabo and Ponce, Puerto Rico 88
7.5.6 Sep 26, 2017: Cytex receives 4 new federal grants 88
7.6 Product News 89
7.6.1 Apr 19, 2018: Corail Hip System Collared Femoral Stem Demonstrates a 29% Lower Revision Risk Compared to Class, According to Independent Joint Registry Data 89
7.6.2 Mar 06, 2018: Exactech Knee System, Ankle, Shoulder Stem, Hip Stem and Computer-Assisted Surgery Technology Headline at Booth 5023, AAOS 2018 Annual Meeting 89
7.6.3 Mar 06, 2018: New Assessment Tool Helps Identify Risk for Post-Surgical Dislocations Following Total Hip Replacement 90
7.6.4 Mar 06, 2018: Neurocognitive Impairment Linked to Worse Outcomes After Total Joint Replacement 91
7.6.5 Jan 08, 2018: MicroPort Orthopedics Attends 12th COA 92
7.6.6 Nov 27, 2017: OrthoPediatrics to Highlight its Products at the 14th Annual International Pediatric Orthopaedic Symposium 94
7.6.7 Aug 11, 2017: Bonovo participated in the Chinese Medical Association of neurosurgery branch of the 16th academic conference 94
7.6.8 Aug 05, 2017: Bonovo participated in the first session of the Great Wall Orthopedic Forum, the 14th Beijing Orthopedic Association (BOA) and the first Beijing - Shanghai Orthopedic Summit meeting 94
7.6.9 Jun 22, 2017: Exactech Expands Presence in Japan with Newly Approved Shoulder, Knee and Hip Replacement Systems 95
7.6.10 May 31, 2017: Depuy Synthes and Ethicon to Showcase Intra Operative Solutions Aiming to Mitigate Surgical Site Infection During Efort Congress 95
7.7 Strategy And Business Planning 96
7.7.1 Dec 11, 2017: Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura 96
8 Appendix 98
8.1 Research Methodology 99
8.1.1 Coverage 99
8.1.2 Secondary Research 99
8.1.3 Primary Research 100
8.1.4 Market Modeling and Forecasting 101
8.1.5 Company Share Analysis 102
8.1.6 Distribution Share Analysis 103
8.1.7 Benchmarking 103
8.2 GlobalData Consulting 103
8.3 Contact Us 104
8.4 Disclaimer 104
List of Figure
1.2 List of Figures
Figure 1: Hip Reconstruction Market, United States, Revenue (USDm), USD Constant, 2015-2025 10
Figure 2: Partial Hip Replacement Market, United States, Revenue (USDm), USD Constant, 2015-2025 13
Figure 3: Primary Hip Replacement Market, United States, Revenue (USDm), USD Constant, 2015-2025 15
Figure 4: Hip Reconstruction Market, United States, Volume (Units), 2015-2025 17
Figure 5: Partial Hip Replacement Market, United States, Volume (Units), 2015-2025 19
Figure 6: Primary Hip Replacement Market, United States, Volume (Units), 2015-2025 21
Figure 7: Hip Reconstruction Market, United States, Company Share (%) 2017 26
List of Table
1.1 List of Tables
Table 1: Hip Reconstruction Market, United States, Revenue (USDm), USD Constant, 2015-2020 11
Table 2: Hip Reconstruction Market, United States, Revenue (USDm), USD Constant, 2021-2025 12
Table 3: Partial Hip Replacement Market, United States, Revenue (USDm), USD Constant, 2015-2020 14
Table 4: Partial Hip Replacement Market, United States, Revenue (USDm), USD Constant, 2021-2025 14
Table 5: Primary Hip Replacement Market, United States, Revenue (USDm), USD Constant, 2015-2020 16
Table 6: Primary Hip Replacement Market, United States, Revenue (USDm), USD Constant, 2021-2025 16
Table 7: Hip Reconstruction Market, United States, Volume (Units), 2015-2020 18
Table 8: Hip Reconstruction Market, United States, Volume (Units), 2021-2025 18
Table 9: Partial Hip Replacement Market, United States, Volume (Units), 2015-2020 20
Table 10: Partial Hip Replacement Market, United States, Volume (Units), 2021-2025 20
Table 11: Primary Hip Replacement Market, United States, Volume (Units), 2015-2020 22
Table 12: Primary Hip Replacement Market, United States, Volume (Units), 2021-2025 22
Table 13: Hip Reconstruction Market, United States, Average Price (USD), 2015-2020 23
Table 14: Hip Reconstruction Market, United States, Average Price (USD), 2021-2025 24
Table 15: Hip Reconstruction Market, United States, Distribution Share by Revenue (USDm), USD Constant, 2017 25
Table 16: Hip Reconstruction Market, United States, Company Share by Revenue (USDm), USD Constant, 2017 27
Table 17: Hip Reconstruction Market Pipeline Products 30
Table 18: Zimmer Biomet Raises USD450 Million in Public Offering of Notes Due 2021 31
Table 19: Amedica Files Registration Statement for Rights Offering of Units for up to USD11.4 Million 33
Table 20: TPG Capital Amends Agreement to Acquire Exactech 35
Table 21: JANA Partners Denies Rumor to Acquire Certain Stake in Zimmer Biomet 37
Table 22: Active Implants Raises USD3.3 Million in Venture Financing 38
Table 23: OrthAlign Raises USD7.6 Million in Financing 39
Table 24: Total Number of Primary Research Participants, Orthopedic Devices Market, by Country 101
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.